Alector, Inc. (ALEC)
| Market Cap | 265.24M |
| Revenue (ttm) | 21.05M |
| Net Income (ttm) | -142.93M |
| Shares Out | 109.15M |
| EPS (ttm) | -1.39 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,337,610 |
| Open | 2.510 |
| Previous Close | 2.560 |
| Day's Range | 2.315 - 2.529 |
| 52-Week Range | 0.870 - 3.400 |
| Beta | 0.63 |
| Analysts | Hold |
| Price Target | 3.33 (+37.04%) |
| Earnings Date | Feb 25, 2026 |
About ALEC
Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer’s disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson’s disease and Lewy body... [Read more]
Financial Performance
In 2025, Alector's revenue was $21.05 million, a decrease of -79.07% compared to the previous year's $100.56 million. Losses were -$142.93 million, 20.1% more than in 2024.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for ALEC stock is "Hold." The 12-month stock price target is $3.33, which is an increase of 37.04% from the latest price.
News
Alector Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Advancing the Alector Brain Carrier (ABC) platform across multiple therapeutic modalities, including antibodies, enzymes, and siRNA, with continued progress across AL137 (ABC-enabled anti-amyloid anti...
Alector to Participate in the TD Cowen 46th Annual Health Care Conference
SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progre...
Alector Appoints Neil Berkley as Chief Financial Officer and Chief Business Officer
SOUTH SAN FRANCISCO, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progre...
Alector, Inc. (ALEC) Presents at BofA Securities CNS Therapeutics Virtual Conference 2025 Transcript
Alector, Inc. (ALEC) Presents at BofA Securities CNS Therapeutics Virtual Conference 2025 Transcript
Alector to Participate in the Bank of America CNS Therapeutics Conference
SOUTH SAN FRANCISCO, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progre...
ALEC Investors Have Opportunity to Join Alector, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES, Nov. 26, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alector, Inc. (“A...
Alector Reports Third Quarter 2025 Financial Results and Provides Business Update
Selected lead candidates AL137 for the company's Alector Brain Carrier (ABC)-enabled anti-amyloid beta antibody in Alzheimer's disease, and AL050 for its ABC-enabled GCase enzyme replacement therapy i...
Clinical Failure Halts Alector's Dementia Program, Company Reduces Workforce
On Tuesday, Alector, Inc. (NASDAQ:ALEC) announced results from the Phase 3 INFRONT-3 trial evaluating latozinemab (AL001) for frontotemporal dementia caused by a progranulin gene mutation (FTD- GRN).
Alector Announces Results from its Phase 3 Clinical Trial of Potential FTD-GRN Therapeutic
Treatment did not slow progression of FTD as measured by the clinical co-primary endpoint Treatment did not slow progression of FTD as measured by the clinical co-primary endpoint
Alector shares plunge after dementia drug fails to slow disease progression
Alector said on Tuesday its experimental drug failed to slow the progression of a rare form of dementia in a late-stage trial, prompting the company to end the study and cut nearly half its workforce.
Alector Announces Topline Results from Latozinemab Phase 3 Trial in Individuals with Frontotemporal Dementia Due to a GRN Mutation and Provides Business Update
SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progre...
4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals
Among the recent momentum standouts in the biotechnology sector, four stocks have drawn considerable investor attention, entering the top 10th percentile of momentum-ranked stocks based on decisive we...
Alector, Inc. - Special Call
Alector, Inc. - Special Call Company Participants Katie Hogan - Senior Director of Corporate Communication & Investor Relations Sara Kenkare-Mitra - President and Head of Research & Development Arnon ...
Alector to Host Virtual Research and Development Event Highlighting PGRN Franchise and Brain Carrier Programs
SOUTH SAN FRANCISCO, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating ...
Alector, Inc. (ALEC) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Alector, Inc. (NASDAQ:ALEC) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 10:00 AM EDT Company Participants Arnon Rosenthal - Co-Founder, CEO & Director Conference Call Pa...
Alector to Participate in Upcoming Healthcare Conferences
SOUTH SAN FRANCISCO, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating p...
Alector, Inc. (ALEC) Q2 2025 Earnings Call Transcript
Alector, Inc. (NASDAQ:ALEC) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Arnon Rosenthal - Co-Founder, CEO & Director Giacomo Salvadore - Chief Medical Officer Kati...
Alector Reports Second Quarter 2025 Financial Results and Provides Business Update
On track to report topline data by mid-Q4 2025 from the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN, a severe, rare form of dementia with no approved treatments Ongoing Phase 2 ...
Alector to Host Second Quarter and Mid-Year 2025 Earnings Conference Call
Call Scheduled for Thursday, August 7, 2025, at 4:30 p.m. ET/1:30 p.m. PT Call Scheduled for Thursday, August 7, 2025, at 4:30 p.m. ET/1:30 p.m. PT
Alector Provides Executive Leadership Update
-- Neil Berkley, M.B.A., appointed Interim Chief Financial Officer, succeeding Marc Grasso, M.D., effective June 20, 2025 -- SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- Alector, In...
Alector to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating p...
Alector Reports First Quarter 2025 Financial Results and Provides Business Update
Topline data from pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN on track for Q4 2025 Completed enrollment in PROGRESS-AD Phase 2 clinical trial of AL101 in early Alzheimer's disea...
Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimer's Disease
--76-week trial is evaluating the safety and efficacy of a progranulin-elevating candidate in slowing disease progression-- --Enrollment completed ahead of schedule-- SOUTH SAN FRANCISCO, Calif., Apri...
Alector, Inc. (ALEC) Q4 2024 Earnings Call Transcript
Alector, Inc. (NASDAQ:ALEC) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Katie Hogan - Senior Director-Corporate Communications and Investor Relations Arnon Rose...
Alector Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Topline data from the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN expected by Q4 2025 Anticipate completing enrollment in the PROGRESS-AD Phase 2 clinical trial of AL101/GSK 452...